Selling a health analytics product to a hospital or government agency is fundamentally different from acquiring individual users. The product needs to be different too.
April 4, 2026 · 10 min read · Africure Analytics
Consumer software optimises for user acquisition, engagement, and retention. Institutional software optimises for trust, compliance, and demonstrated value. These are different design problems with different success criteria.
An individual user signs up, tries the product, and decides within minutes whether to continue. An institution evaluates the product over weeks or months. There are procurement processes, compliance reviews, legal assessments, and stakeholder approvals. The decision involves people who will never use the product but who control the budget.
This means the product needs to satisfy two audiences: the end users who interact with it daily, and the decision-makers who approve the purchase. The end users care about usability. The decision-makers care about governance, data security, audit trails, and whether the claims in the proposal match what the product actually does.
The procurement timeline for a government health agency in sub-Saharan Africa is typically 3-9 months from initial inquiry to signed agreement. During that period, the product will be reviewed by the requesting department, the IT unit, the procurement office, the legal team, and sometimes an external technical evaluator. Each reviewer has different concerns. The requesting department wants to know if the tool will solve their problem. The IT unit wants to know if it integrates with their infrastructure. The legal team wants to know about data handling and liability. The procurement office wants to know about pricing structure and contract terms.
Building a product that survives this gauntlet requires addressing all of these concerns in the product itself, not just in the sales materials. The governance features need to be built, not promised. The data handling needs to be documented and verifiable, not described in aspirational language. The technical specifications need to be accurate, not optimistic. Every claim made during procurement will be tested during the evaluation, and a single discrepancy between the claim and the product can end the process.
Consumer products can get away with aspirational marketing. Institutional products cannot. When a proposal says the platform provides 'role-based access control with audit logging,' someone on the procurement committee will verify that claim. When the proposal says the prediction model was 'validated on a Nigerian patient population,' someone will ask for the reference.
We write product descriptions, solution pages, and proposals with this standard in mind. Every capability we claim is implemented. Every model we reference is published. Every governance feature we describe is built into the platform. This sounds obvious, but it is surprisingly rare in health tech.
The defensibility standard applies to performance claims as well. We do not describe our models as 'state-of-the-art' or 'highly accurate' because those terms are subjective and unverifiable. We state the AUC, the calibration performance, and the validation approach. We name the source population and the sample size. We provide the published reference. A technical evaluator can verify every claim independently, and that verifiability is what builds trust during procurement.
This discipline extends to feature descriptions. We do not list features that are planned but not built. We do not describe integrations that have not been tested. When a feature is under development, we say so explicitly and provide a realistic timeline. Overpromising during procurement and underdelivering during implementation is the fastest way to lose institutional trust, and institutional trust, once lost, is almost impossible to recover.
Institutional sales do not end at the contract signing. The implementation phase is where the product proves whether it can deliver what the procurement process promised. A smooth implementation builds the reference relationship that leads to future contracts. A difficult implementation creates a cautionary tale that circulates through the institution's professional network.
Our implementation approach includes a structured onboarding process: project setup, role assignment, data upload walkthrough, and a training session tailored to the institution's specific use case. We do not rely on generic documentation or video tutorials because institutional users expect personalised support. A programme manager at a government health agency does not want to watch a YouTube video. They want someone to walk them through the tool using their data and their workflow.
Post-implementation support is equally important. When a district health manager calls with a question about a specific number in a report, they need an answer from someone who understands both the platform and the epidemiology. First-line support that can only read from a script is worse than no support at all. Our support model pairs technical knowledge with domain expertise so that questions about the analytics get analytical answers, not generic troubleshooting responses.
For institutional sales, the product is not just the software. It is the relationship, the transparency, the responsiveness, and the demonstrated competence. A hospital will not use a prediction model from a company that overstates its capabilities, even if the model itself is good.
We treat trust as a product feature. Honest scope statements, published references, transparent model coefficients, and clear governance infrastructure are not overhead. They are the reason institutional partners choose to work with us.
Trust compounds over time. An institution that has a good experience with the first project is predisposed to expand the engagement. A hospital that deployed a diabetes risk calculator and found it reliable will consider deploying additional models for other conditions. A government agency that used the platform for one programme evaluation will consider it for the next one. Each successful engagement reduces the procurement overhead for the next one because the trust foundation is already established.
April 1, 2026 / 10 min read
Useful risk analytics starts with the workflow it needs to support. Model novelty matters far less than whether the output fits real review, reporting, and follow-through.
April 1, 2026 / 10 min read
Population analytics works best when it reflects local burden, reporting structures, and the real operational environment.
April 1, 2026 / 10 min read
Image models can add analytical value when scope, validation, and reporting boundaries are described with precision.